Abstract:Purpose: Myelodysplastic syndromes (MDS), is characterized by clinical heterogeneity and varying prognoses. Reliable prognostic models are essential to stratify MDS patients and optimize clinical management. Although incorporating molecular information into MDS prognostic models improves their predictive ability, limitations of next-generation sequencing panels and potential heterogeneity among MDS patients with different karyotypes hinder their clinical translation. Methods: In total, 237 normal karyotype (NK) MDS patients from the First Affiliated Hospital of Zhejiang University School of Medicine were used as the derivation set to investigate the molecular frequency and prognostic spectrum. A parsimonious molecular-clinical model was developed with overall survival (OS) as the endpoint and compared with other models using the concordance index as the primary evaluation index. An external independent validation set from the International Working Group for Prognosis in MDS cohort(691 NK MDS patients) was used to evaluate the model generalization ability. Results: In NK MDS, the gene mutation frequency spectrum is similar to the overall MDS population, the differences mainly lie in the prognostic spectrum. Genes such as TP53, previously associated with MDS prognoses have lost their prognostic value. Therefore, a seven-parameter molecular-clinical prognostic model called the Molecular Prognostic Scoring System for NK MDS (NK-PSS-M) was developed based on a specific molecular prognostic spectrum of NK MDS. The model includes age, hemoglobin, platelet count, blast percentage, CEBPA, RUNX1, and U2AF1. The NK-PSS-M model allows for personalized risk assessment based on patient characteristics, with higher scores indicating a greater risk and poorer prognosis. In addition, we developed a five-class classification system based on these scores, which differentiates patients across risk categories and predicts outcomes, such as OS and LFS(Figure 1 A and B). The performance of NK-PSS-M was comparable to that of the Molecular International Prognostic Scoring System(IPSS-M), and it significantly outperformed IPSS-R and other molecular prediction models based on it. The above results were confirmed in the external independent validation cohort(Figure 1C). Our transcriptomics analysis revealed that the low-risk group defined by NK-PSS-M demonstrated significant activation of the inflammatory pathway, and immune activation, which is consistent with the current understanding of the immunological landscape of MDS. Conclusion: The NK-PSS-M model improved the risk stratification of non-molecular models and provided a reliable alternative to the IPSS-M. In addition, we demonstrated the molecular heterogeneity of MDS across different cytogenetics and emphasized the importance of developing cytogenetics-specific prognostic models.

[Application of Two-parameter Scoring System Based on CD105 and CD117 in MDS Diagnosis].

[Karyotype Analysis of 283 Cases of Myelodysplastic Syndrome].

The Molecular Prognostic Scoring System for Normal Karyotype Myelodysplastic Syndromes

Analysis of the Karyotype Abnormalities and Its Prognostic in 298 Patients with Myelodysplastic Syndrome

Establishment and Validation of an Updated Diagnostic FCM Scoring System Based on Pooled Immunophenotyping in CD34+ Blasts and Its Clinical Significance for Myelodysplastic Syndromes

Side scatter ratio of the CD105-positive and CD105-negative red blood cell fractions is useful for the detection of low-grade myelodysplastic neoplasms by flow cytometry

A New Diagnostic Approach for Myelodysplastic Neoplasms Using a Combination of Scores Based on Flow Cytometry and Automated Hematology Sysmex XN Analyzers

Flow cytometric scoring system (FCMSS) assisted diagnosis of myelodysplastic syndromes (MDS) and the biological significance of FCMSS-based immunophenotypes: FCMSS-assisted Diagnosis of MDS

Correlation Between Bone Marrow Blasts Counts with Flow Cytometry and Morphological Analysis in Myelodysplastic Syndromes

[Research Advances in Value of Flow Cytometric Immunophenotyping in Diagnosis and Prognostic Evaluation of Myelodysplastic Syndrome].

[The Value of Flow Cytometry for the Differential Diagnosis Between Refractory Cytopenia with Multiple Dysplasia and Aplastic Anemia].

Expression and significance of CD34, CD117 on bone marrow mononuclear cells of patients with myelodysplastic syndrome

[Role of Flow Cytometry in the Diagnosis of Chronic Myeloid Leukemia].

Clinical study of the number of circulating CD34~+ cells in the peripheral blood from patients with myelodysplastic syndromes

Differentiation and expression of membrane hemopoietic cytokine receptors on CD34+ bone marrow cells in patients with myelodysplastic syndromes

Complete Blood Counts and Research Parameters in the Detection of Myelodysplastic Syndromes

Abnormalities of CD34+ cells differentiation and bone marrow cell cycle in myelodysplastic syndrome

Clinical Analysis of Myelodysplastic Syndrome

Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes: results of a European LeukemiaNET study

Evaluation of the Clinical Significance of Immunophenotyping in Myelodysplastic Syndrome.

[The Application of a New Prognostic Score System for 435 Cases of Primary Myelodysplastic Syndrome Diagnosed with WHO Classification].